Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Free Cash Flow: 2016-2025

Historic Free Cash Flow for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to -$50.4 million.

  • Rocket Pharmaceuticals' Free Cash Flow rose 6.19% to -$50.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$202.8 million, marking a year-over-year decrease of 0.23%. This contributed to the annual value of -$215.6 million for FY2024, which is 2.00% down from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Free Cash Flow stood at -$50.4 million for Q3 2025, which was down 2.76% from -$49.0 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' 5-year Free Cash Flow high stood at -$24.6 million for Q1 2021, and its period low was -$61.8 million during Q3 2023.
  • In the last 3 years, Rocket Pharmaceuticals' Free Cash Flow had a median value of -$55.0 million in 2023 and averaged -$53.0 million.
  • In the last 5 years, Rocket Pharmaceuticals' Free Cash Flow crashed by 83.09% in 2021 and then skyrocketed by 42.42% in 2023.
  • Quarterly analysis of 5 years shows Rocket Pharmaceuticals' Free Cash Flow stood at -$32.9 million in 2021, then plummeted by 79.37% to -$59.0 million in 2022, then soared by 42.42% to -$34.0 million in 2023, then plummeted by 39.03% to -$47.3 million in 2024, then increased by 6.19% to -$50.4 million in 2025.
  • Its Free Cash Flow was -$50.4 million in Q3 2025, compared to -$49.0 million in Q2 2025 and -$56.2 million in Q1 2025.